ArticleActa pharmacologica Sinica2019
Silk fibroin peptide suppresses proliferation and induces apoptosis and cell cycle arrest in human lung cancer cells.
Article in Acta pharmacologica Sinica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles.RSC advances · 2026Article
- Caddisfly Silk-Polycaprolactone Foams: Physicochemical and Biological Properties of Nature-Inspired Biomaterials.Journal of functional biomaterials · 2025Article
- Therapeutic Potential of Hongjam in A Diethylnitrosamine and Thioacetamide-induced Hepatocellular Carcinoma Mouse Model.Journal of cancer prevention · 2024Article
- Therapeutic Peptides for Treatment of Lung Diseases: Infection, Fibrosis, and Cancer.International journal of molecular sciences · 2023Review
- Review
- A novel silk fibroin protein-based fusion system for enhancing the expression of nanobodies in Escherichia coli.Applied microbiology and biotechnology · 2022Article
- Research progress of natural silk fibroin and the application for drug delivery in chemotherapies.Frontiers in pharmacology · 2022Review
- Silk Fibroin Hydrogels Could Be Therapeutic Biomaterials for Neurological Diseases.Oxidative medicine and cellular longevity · 2022Review
- Article
- Cyclometalated Ru(II) β-carboline complexes induce cell cycle arrest and apoptosis in human HeLa cervical cancer cells via suppressing ERK and Akt signaling.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2021Article
- Silk fibroin safety in the eye: a review that highlights a concern.BMJ open ophthalmology · 2020Review
- Silk peptide treatment potentiates natural killer cell activityPharmaceutical biology · 2019Article
- Oral Administration of Silk Peptide Enhances the Maturation and Cytolytic Activity of Natural Killer Cells.Immune network · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silkworm cocoon was recorded to cure carbuncle in the Compendium of Materia Medica. Previous studies have demonstrated that the supplemental silk protein sericin exhibits anticancer activity. In the present study, we investigated the effects of silk fibroin peptide (SFP) extracted from silkworm cocoons against human lung cancer cells in vitro and in vivo and its possible anticancer mechanisms. SFP that we prepared had high content of glycine (~ 30%) and showed a molecular weight of ~ 10 kDa. Intragastric administration of SFP (30 g/kg/d) for 14 days did not affect the weights, vital signs, routine blood indices, and blood biochemical parameters in mice. MTT assay showed that SFP dose-dependently inhibited the growth of human lung cancer A549 and H460 cells in vitro with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.